Intimacy · Reference
PT-141 Dosage and How to Use It: Units, mL, mg and Timing
This page explains the PT-141 dosage Pepti prescribes, what the units on the syringe mean, a chart that converts units to millilitres and milligrams, how to use PT-141 on the day, how long a vial lasts, the PT-141 + Oxytocin vial, what the published trials used, and the side effects to know about. It covers how Pepti's PT-141 is typically prescribed, not dosing protocols from the internet. Nothing here is a reason to change your own dose.
Treatments mentioned
At Pepti, PT-141 is prescribed as 0.50 mL, which is 50 units on a U-100 insulin syringe, injected under the skin 2 to 4 hours before sexual activity, no more than 4 doses a month. The vial is 5 mL at 2 mg/mL, so each dose carries 1 mg of PT-141 (bremelanotide) and the vial holds 10 doses. It is used on the occasion, not on a daily schedule, and never more than once in 24 hours. Your physician sets your directions after reviewing your intake, and your exact dose and units are printed on the vial.
This page explains the PT-141 dosage Pepti prescribes, what the units on the syringe mean, a chart that converts units to millilitres and milligrams, how to use PT-141 on the day, how long a vial lasts, the PT-141 + Oxytocin vial, what the published trials used, and the side effects to know about. It covers how Pepti's PT-141 is typically prescribed, not dosing protocols from the internet. Nothing here is a reason to change your own dose.
PT-141 Dosage and How to Use It
The short answer
| Product | Vial | Typical directions | PT-141 per dose | Doses per vial | Price |
|---|---|---|---|---|---|
| PT-141 | 5 mL, 2 mg/mL (10 mg per vial) | Inject 0.50 mL (50 units) subcutaneously 2 to 4 hours prior to sexual activity. No more than 4 doses per month | 1 mg | 10 | $259/mo |
| PT-141 + Oxytocin | 5 mL, PT-141 2 mg/mL + oxytocin 1 mg/mL (10 mg PT-141 / 5 mg oxytocin per vial) | Inject 0.10 mL (10 units) subcutaneously 2 to 4 hours prior to sexual activity. No more than 8 doses per month | 0.2 mg, with 0.1 mg oxytocin | 50 | $259/mo |
Every price is all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. These are the typical printed directions; your own directions are the ones on your vial.
PT-141 Dosage and How to Use It
PT-141 dosage in units, mL and mg
Pepti's directions are written in two forms, millilitres and units, because prescriptions are written in millilitres and insulin syringes are marked in units. On a U-100 insulin syringe, 1 unit is 0.01 mL, so 100 units is 1 mL and 50 units is 0.50 mL. A unit is a volume mark on the barrel, not a measure of how strong the medication is. Units only mean something alongside the concentration on the label.
Pepti's PT-141 is supplied at 2 mg/mL, so:
| What you read | Value | Where it comes from |
|---|---|---|
| Dose volume | 0.50 mL | Printed on the vial |
| On a U-100 insulin syringe | 50 units | 0.50 mL x 100 units per mL |
| Concentration | 2 mg/mL | Printed on the vial |
| PT-141 per dose | 1 mg | 2 mg/mL x 0.50 mL |
| Total in the vial | 10 mg in 5 mL | Printed on the vial |
| Doses per vial | 10 | 5 mL divided by 0.50 mL |
| Monthly ceiling | 4 doses | Printed on the vial |
That arithmetic is a way to read a label, not a way to set a dose. A vial labelled 10 mg is not a 10 mg dose: it is ten 1 mg doses. If your label and your syringe seem to disagree, do not dose; message your care team. How long does a peptide vial last explains every number on a vial label in more detail.
PT-141 Dosage and How to Use It
PT-141 dosage chart: units to mL to mg
The chart below is the conversion for a 2 mg/mL vial, drawn with a U-100 insulin syringe. It is math only. It is not a menu of doses, and the only line that applies to you is the one that matches the number printed on your vial.
| Syringe mark (U-100) | Volume | PT-141 from a 2 mg/mL vial |
|---|---|---|
| 10 units | 0.10 mL | 0.2 mg |
| 20 units | 0.20 mL | 0.4 mg |
| 25 units | 0.25 mL | 0.5 mg |
| 30 units | 0.30 mL | 0.6 mg |
| 40 units | 0.40 mL | 0.8 mg |
| 50 units (Pepti's typical directions) | 0.50 mL | 1 mg |
| 75 units | 0.75 mL | 1.5 mg |
| 100 units | 1 mL | 2 mg |
The rule behind every row: units divided by 100 gives millilitres, and millilitres multiplied by 2 gives milligrams. A chart from another source, written for a different concentration, gives different milligram figures for the same units. That is the main reason not to dose from a chart, including this one.
The PT-141 + Oxytocin vial
The PT-141 + Oxytocin vial is a different concentration mix and a different draw. Its typical directions are 0.10 mL, 10 units, 2 to 4 hours before sexual activity, no more than 8 doses a month. Each 10 unit draw delivers 0.2 mg of PT-141 and 0.1 mg of oxytocin together, in fixed proportion; there is no way to take more of one and less of the other from the same vial. The two labels are not interchangeable: 50 units from the PT-141 vial and 10 units from the combination vial are different products with different directions. More is in what is PT-141 + Oxytocin.
The Pen
PT-141 also comes as a 3 mL pre-filled pepti Pen cartridge containing 10 mg of PT-141, used in a reusable click-dial injector. It is dosed by the pen's dial rather than drawn with a syringe, so the units chart above does not apply to it; the directions come printed with your prescription. It is the same medication, and the comparison is in vial vs pen. PT-141 + Oxytocin is a vial only.
PT-141 Dosage and How to Use It
How to use PT-141
PT-141 is not a daily medication. Each dose is taken for an occasion, and each one stands on its own. This is the practical sequence, in the order it happens.
1. Check the label first
Read the dose, the timing window and the monthly ceiling on your vial. The label is the instruction; this page is background. Check the beyond-use date as well, because a PT-141 vial can sit in the fridge for weeks between uses.
2. Time it 2 to 4 hours ahead
Pepti's directions say 2 to 4 hours before sexual activity. The FDA-approved bremelanotide product's label reports peak blood levels about an hour after a dose and a half-life of about 2.7 hours, and it directs dosing at least 45 minutes before activity. The label also states that how long the effect lasts has not been fully characterised. Your own directions say which window applies to you.
3. Draw and inject under the skin
Use a fresh sterile syringe every time, wipe the vial stopper and the skin with an alcohol prep pad, draw to the mark printed on your label, and inject into the fat layer under the skin, not the muscle. The abdomen and thigh are the usual sites. Rotate sites, which matters here because injection-site reactions were among the more common events in the trials. Technique is covered step by step in how to inject peptides safely.
4. One dose, then wait
Never take a second dose within 24 hours. The approved label states that consecutive doses within 24 hours have not been shown to add anything and may have additive effects on blood pressure. Taking an extra dose because the first did not seem to work is the one thing prescribers ask patients not to do.
5. Expect the first dose to be about side effects
Nausea, when it happens, usually starts within an hour and lasts about two, and it is most common with the first dose. The approved label notes that it improved for most trial participants by the second dose. Prescribers suggest taking a first dose on an occasion where a poor response would not matter.
6. Back in the fridge
Return the vial to the refrigerator. Vials ship refrigerated with ice packs and the beyond-use date runs from first puncture. How to store peptides covers storage.
Directions say What it means in practice 0.50 mL (50 units) Draw to the 50 mark on a U-100 insulin syringe Subcutaneously Into the fat layer, abdomen or thigh, rotating sites 2 to 4 hours prior to sexual activity Dose ahead of time, not at the moment No more than 4 doses per month A ceiling, not a target Once in 24 hours at most No second dose the same day, from the approved label
PT-141 Dosage and How to Use It
How long a PT-141 vial lasts
PT-141 is used on occasions, so a vial is not consumed on a calendar the way a weekday peptide is. The arithmetic:
| Step | Value |
|---|---|
| Dose | 50 units, 0.50 mL, 1 mg |
| Doses per vial | 10 (5 mL divided by 0.50 mL) |
| Ceiling | 4 doses a month |
| At the ceiling | 10 doses cover about ten weeks |
| Used less often | The beyond-use date on the label decides when the vial is replaced |
The PT-141 + Oxytocin vial holds 50 doses at 0.10 mL, capped at 8 a month, so its dose count will almost always outlast its beyond-use date. Either way, one vial per fill, and doses left in a vial are not a reason to use it more often. If you have questions about when your next vial ships, message your care team.
PT-141 Dosage and How to Use It
Why the monthly ceiling exists
The cap is a safety limit, not a way to ration the vial; the approved label's own ceiling is eight a month, and whatever number is on your label is the one to follow. It comes from two effects described on that label:
| Effect | What was reported | Why it limits frequency |
|---|---|---|
| Blood pressure | A transient mean rise of about 6 mmHg systolic and 3 mmHg diastolic, peaking two to four hours after a dose, usually back to baseline within twelve | Each dose adds hours of raised blood pressure |
| Focal hyperpigmentation | 1% of women dosing up to eight times a month; 38% of people dosed daily for eight days in a separate study; face, gums and breasts; not always reversible | Risk rises with more frequent dosing |
PT-141 Dosage and How to Use It
What the trials used, and why that is not your dose
PT-141 has a real human trial record, and its doses are often quoted online as if they were protocols. They were not designed as one:
| Study | Who | How it was dosed |
|---|---|---|
| Phase 2b, Women's Health, 2016 | Premenopausal women, 327 analysed | 0.75, 1.25 or 1.75 mg subcutaneously, as desired, against placebo |
| RECONNECT, two phase 3 trials, Obstetrics & Gynecology, 2019 | 1,267 premenopausal women with acquired, generalised hypoactive sexual desire disorder | 1.75 mg by single-dose autoinjector, self-injected as needed, for 24 weeks |
| 52-week extension, 2019 | 684 women who chose to continue | Same as needed use; most used it two to three times a month |
| Two 2004 studies, International Journal of Impotence Research | Healthy men and men with mild-to-moderate erectile dysfunction | Subcutaneous doses above 1 mg in healthy men, and 4 mg and 6 mg in men who responded inadequately to sildenafil; intranasal doses above 7 mg |
| 2006 crossover, Journal of Sexual Medicine | 18 premenopausal women with sexual arousal disorder | A single 20 mg intranasal dose; intranasal delivery was later dropped |
The honest reading: the trials used a fixed autoinjector, intranasal sprays or single doses in a clinic, and none of them tested a compounded 2 mg/mL multi-dose vial. The phase 3 effects on desire and distress were statistically significant and modest in absolute size. That is why your directions come from a physician who has reviewed your intake, not from a study table. The evidence in detail is in PT-141 benefits and what is PT-141.
PT-141 Dosage and How to Use It
What changes the directions
Your physician sets your directions after reviewing your intake. Things that can lead to different directions, or a different product, include:
| What can change | How it shows up |
|---|---|
| PT-141 alone or with oxytocin | PT-141 + Oxytocin has its own label: 10 units, up to 8 doses a month |
| Vial or Pen | The Pen is dosed by dial instead of syringe units |
| Blood pressure or heart history | Uncontrolled hypertension and known cardiovascular disease are reasons it is not prescribed |
| Your other medications | It can slow gastric emptying and reduce absorption of oral medicines taken around the same time, and it should not be used with oral naltrexone |
| How you respond | Marked nausea, new skin darkening or anything unexpected goes to your physician, who may revise your directions |
When directions change, the new numbers are printed on the new label. Never carry a number over from a previous fill. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.
PT-141 Dosage and How to Use It
Side effects, in summary
The full picture is in PT-141 side effects. Because the same active ingredient carries an FDA label, its side effects are better described than for most peptides.
| What is reported | How often in the phase 3 trials | What to do |
|---|---|---|
| Nausea | 40% of women vs 1.3% on placebo | Usually eases after the first dose; tell your care team if it is marked |
| Flushing | 20% | Usually short-lived |
| Injection-site reactions | 13% | Rotate sites |
| Headache | 11% | Report it if it persists |
| Vomiting | 5% | Report it |
| New darkening of skin, gums or breasts | 1% at up to eight doses a month | Report it promptly |
| Chest pain, a severe headache, trouble breathing, or an erection lasting more than four hours | Not routine | Call 911 or go to an emergency department, then tell your physician |
Who should not take PT-141, or should discuss it first: anyone with uncontrolled high blood pressure or heart disease; anyone taking oral naltrexone; anyone with a history of melanoma or atypical moles, because of the pigmentation warning; anyone pregnant or breastfeeding, where it is not used. Bremelanotide is not named on the 2026 WADA Prohibited List, but tested athletes should check their own sport's current rules.
The active ingredient, bremelanotide, is the basis of an FDA-approved drug, approved on 21 June 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Compounded PT-141 is a different formulation, a 2 mg/mL multi-dose vial or Pen cartridge, and it is not FDA approved; compounded medications are not FDA approved.
PT-141 Dosage and How to Use It
Where to get PT-141 prescribed
PT-141 cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for what is in the vial: identity, purity, sterility and concentration are untested, so even the concentration your units chart depends on is unknown. The prescription route:
- Complete a free online intake covering your history, medications and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial, with sterile syringes and alcohol prep pads.
- Your physician stays reachable for questions and dose changes.
Pepti prescribes PT-141 in every state except Oklahoma, plus DC Step by step: how to get PT-141 prescribed online. What to check on any provider is in where to buy PT-141 online. How it compares with neighbouring products: kisspeptin vs PT-141, PT-141 vs Melanotan II and peptides for libido.
References
What this is based on.
References
- Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder · Obstetrics & Gynecology (2019) · PMID 31599847
- Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial · Women's Health (London) (2016) · PMID 27181790
- Clayton AH, Kingsberg SA, Portman D, Sadiq A, Krop J, Jordan R, Lucas J, Simon JA. Safety Profile of Bremelanotide Across the Clinical Development Program · Journal of Women's Health (2022) · PMID 35147466
- Pfaus JG, Sadiq A, Spana C, Clayton AH. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women · CNS Spectrums (2022) · PMID 33455598
- Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction · International Journal of Impotence Research (2004) · PMID 14963471
- Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra · International Journal of Impotence Research (2004) · PMID 14999221
- Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response · Urology (2005) · PMID 15833522
- Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction · Annals of the New York Academy of Sciences (2003) · PMID 12851303
- Kingsberg SA, Clayton AH, Portman D, et al.. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials · Obstetrics & Gynecology (2019) · PMID 31599840
- Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease · JAMA (2005) · PMID 16414947
- Nehra A, Jackson G, Miner M, Billups KL et al.. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease · Mayo Clin Proc (2012) · PMID 22862865
- Carani C, Isidori AM, Granata A, Carosa E, Maggi M, Lenzi A, Jannini EA. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients · J Clin Endocrinol Metab (2005) · PMID 16204360
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
PT-141 Dosage and How to Use It, answered.
At Pepti, PT-141 is typically prescribed as 0.50 mL, which is 50 units on a U-100 insulin syringe, injected subcutaneously 2 to 4 hours before sexual activity, no more than 4 doses a month. From the 2 mg/mL vial that is 1 mg per dose. Your physician sets your directions after reviewing your intake, and your exact dose is printed on the vial.
The number printed on your vial. Pepti's typical PT-141 directions are 50 units, which is 0.50 mL on a U-100 insulin syringe. The PT-141 + Oxytocin vial is typically 10 units. The two are not interchangeable.
From a 2 mg/mL vial, 1 mg. 25 units is 0.5 mg and 10 units is 0.2 mg. Those figures only hold at 2 mg/mL.
Inject the dose on your label under the skin of the abdomen or thigh, 2 to 4 hours before sexual activity, with a fresh sterile syringe. Take no more than one dose in 24 hours and no more than the monthly number on your label. Put the vial back in the fridge afterwards.
Pepti's directions say 2 to 4 hours before. The approved bremelanotide label directs at least 45 minutes before and reports peak blood levels at about one hour. Your own label says which window applies to you.
No more than once in 24 hours, and no more than the monthly ceiling on your label: 4 doses a month on Pepti's typical PT-141 directions, 8 on the PT-141 + Oxytocin directions. The ceiling exists because each dose raises blood pressure for a few hours and frequent dosing raises the risk of skin darkening.
No. The approved label states that consecutive doses within 24 hours have not been shown to add anything and may add to the blood pressure effect. If a dose did not seem to work, message your care team rather than adjusting anything yourself.
A vial holds 10 doses. At the ceiling of 4 a month, that is about ten weeks; used less often, the beyond-use date printed on the label decides when it is replaced.
Typically 0.10 mL, 10 units, 2 to 4 hours before sexual activity, no more than 8 doses a month. Each dose delivers 0.2 mg PT-141 and 0.1 mg oxytocin, and the vial holds 50 doses.
No. The phase 3 trials used a 1.75 mg single-dose autoinjector. Pepti's PT-141 is a 2 mg/mL multi-dose vial with physician-set directions, typically 1 mg per dose. The compounded vial has not itself been trialled.
No. Pepti vials are multi-dose solutions shipped ready to use, with sterile syringes and alcohol prep pads. Nothing is reconstituted at home.
Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.